Abstracts
Skip to Late-Breaking Abstracts »
Poster Presentation Dates
All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.
Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).
| # | Title | Authors | Category | Keywords |
|---|---|---|---|---|
| O60 | Tumor cell-intrinsic defects in STING pathway signaling and IFN-β gene regulation | Blake Flood, BS; Leticia Corrales; Thomas F. Gajewski, MD, PhD; | Immune-stimulants and immune modulators | Cytokine; Gene expression; Inflammation; TLR |
| O61 | Myeloid Cell-Targeted miR-146a Mimic Alleviates NF-κB-Driven Cytokine Storm without Interfering with CD19-Specific CAR T-cell Activity against B-Cell Lymphoma | Marcin Kortylewski, PhD; Yu-Lin Su; Xiuli Wang, PhD; Mati Mann; Dayson F. Moreira, PhD; Zhuoran Zhnag; Ching Ouyang; Piotr Swiderski; Stephen J. Forman, MD; David Baltimore, PhD; Ling Li; Guido Marcucci; Mark Boldin; | Immune-stimulants and immune modulators | CAR T cells; Cytokine; Inflammation; Leukemia/Lymphoma; Monocyte/Macrophage; Myeloid cells |
| P608 | ATOR-1017, a 4-1BB antibody developed for tumor-directed immunotherapy of cancer | Doreen Werchau, BS; Anna Rosen, MSc; Mia Eriksson; Sofia Järnum, PhD; Christina Furebring, PhD; Karin Enell Smith, PhD; | Immune-stimulants and immune modulators | Antibody; Costimulation; NK/NK T cell; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P609 | Fc-silenced bispecific antibodies targeting PD-L1 and 4-1BB combine checkpoint blockade and T-cell co-stimulation to promote anti-tumor activity | Alexander Muik, PhD; Isil Altintas, PhD; Friederike Gieseke; Theodora Salcedo; Saskia Burm; Mustafa Diken; Christian Grunwitz; Danita Schuurhuis; Sebastian Kreiter; David Satijn; Özlem Türeci; Esther Breij, PhD; Ugur Sahin; Maria Jure-Kunkel; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Costimulation |
| P610 | Claudin18.2 bispecific T-cell engager for gastric cancer immunotherapy | Sribalaji Lakshmikanthan, PhD; Swarna Pandian, PhD; Zusheng Li; Eugene Chan, MD; Robert Markelewicz, MD; Timothy L. Wyant, PhD; Sribalaji Lakshmikanthan, PhD; | Immune-stimulants and immune modulators | Antibody; Solid tumors; T cell; Targeted therapy |
| P611 | Layer-by-Layer nanoparticles for interleukin-12 delivery | Antonio E. Barberio, BSE; Sean G. Smith, PhD; Santiago Correa; Cathy Nguyen; Paula T. Hammond; Darrell J. Irvine, PhD; Mariane Melo; Talar Tokatlian; | Immune-stimulants and immune modulators | Cytokine; Immune toxicity; Solid tumors; Tumor microenvironment |
| P612 | Using a novel synthetic biology platform to generate a homogenous dipegylated IL-10 with native potency | Carolina E. Caffaro, PhD; Jerod L. Ptacin, PhD; Yelena Pavlova; Jasmine T. Nguyen; Kristine San Jose-Galli; Gavin Hong; Lina Ma, PhD; Nicole Acuff; Taylor Ismaili, MS; Kelsea Loescher; Ingrid B. Joseph, PhD; Jill Mooney, PhD; Joseph Leveque, MD; Marcos E. Milla, PhD; | Immune-stimulants and immune modulators | Cytokine; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P613 | Discovery of pharmacologically differentiated Interleukin 15 (IL-15) agonists employing a synthetic biology platform | Carolina E. Caffaro, PhD; Jerod L. Ptacin, PhD; Robert W. Herman; Lina Ma, PhD; David B. Chen; Ingrid B. Joseph, PhD; Marcos E. Milla, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; CAR T cells; Checkpoint blockade; Cytokine; Immune adjuvant; NK/NK T cell; Solid tumors; T cell; T cell lineages; Tumor microenvironment |
| P614 | Development of a cancer gene therapy approach based on encoding a single chain IL-12 transgene in an oncolytic T-SIGn virus vector | Sam Illingworth; Manuela Zonca; Ana Silva; Alicia Belmonte; Nalini Marino; Carla Cerqueira; Lorna Slater; Katy West; Sara Siebel; Samantha Bucktrout; Fred Ramsdell, PhD; Paul Cockle; Brian R. Champion, PhD; | Immune-stimulants and immune modulators | Cytokine; Gene expression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P615 | Novel immune-cell targeted IL2v to deliver IL-2R signaling to tumor reactive T cells via PD-1 whilst blocking the PD-1 pathway | Laura Codarri Deak; Valeria Nicolini; Laura J. Lauener, Mrs.; Stefan Seeber, Dr.; Marine Richard; Esther Bommer; Maria Karagianni, Mrs.; Johannes Sam, Dr.; Ramona Schlenker, Dr.; Marisa Mariani, Dr.; Petra Schwalie, Dr.; Sylvia Herter, PhD; Marina Bacac, Dr.; Inja Waldhauer, Dr.; Anne Freimoser-Grundschober, Dr.; Volker Teichgräber, Dr.; Christian Klein, Dr rer nat; Pablo Umana, PhD; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Cytokine; Tumor infiltrating lymphocytes (TILs) |
| P616 | A novel anti-tumor anti-PDL1-IL7 immunocytokine targeting lymphocytes | Feifei Cui, PhD; Lei Fang; Haijuan Gu; Yuanyuan Yang; Zhengyi Wang; Bingshi Guo; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Cytokine; T cell |
| P617 | Delivery of Interleukin-2 to the Acidic Tumor Microenvironment by Ultra-pH Sensitive Nanoparticles for Immunotherapy | Xinliang Ding, PhD; Jason B. Miller, PhD; Ashley Campbell; Jonathan Almazan; Tian Zhao; | Immune-stimulants and immune modulators | Cytokine; Solid tumors; Targeted therapy; Tumor microenvironment |
| P618 | MK1169, a peptide unrelated to IL-2, is a potent IL-2Rβγc receptor agonist | William J. Dower, PhD; Steven E. Cwirla, BA; Blake M. Williams, MS; Praechompoo Pongtornpipat, MS; Prarthana Joshi, ME; Sandra M. Wang, BSc; Alice V. Bakker, BA; Michael C. Needels, PhD; Ronald W. Barrett, PhD; | Immune-stimulants and immune modulators | Cytokine; T cell |
| P619 | NKTR-255, a polymer-conjugated IL-15 receptor agonist, enhances efficacy of therapeutic monoclonal antibodies with ADCC activity in solid tumor models | Saul Kivimae, PhD; Takahiro Miyazaki, MS; Rhoneil Pena; Wildaliz Nieves, PhD; Andrew Moffett; Phi Quach, BS PhD; Lawrence Chinn; Marlene Hennessy, BS; Loui Madakamutil; Jonathan Zalevsky, PhD; | Immune-stimulants and immune modulators | Cytokine; NK/NK T cell; Solid tumors |
| P620 | Complementary effects of RNA encoded, extended half-life IL2 and IL7 synergize in modulating T cell responses and antitumoral efficacy. | Lena M. Kranz; Lena M. Kranz; Mathias Vormehr, PhD; Jan Dieckmann, PhD; Claudia Lindemann; David Eisel; Alexander Muik, PhD; Sina Fellermeier-Kopf; Friederike Gieseke; Bodo Tillmann; Sonja Witzel; Marlen Lepper; Mustafa Diken; Sebastian Kreiter, MD; Veronika Jahndel; Özlem Türeci; Ugur Sahin; | Immune-stimulants and immune modulators | Cytokine; Immune adjuvant; T cell; Vaccine |
| P621 | Nanoparticle-mediated Tumor Cell Expression of mIL-12 via Systemic Gene Delivery Treats Syngeneic Models of Murine Lung Cancers | Hye-Hyun Ahn, PhD; Christine Carrington; Heng-wen Liu; Yizong Hu; Christy Ng; Hwanhee Nam; Andrew Park; Catherine Stace; Will West, PhD; Hai-Quan Mao, PhD; Martin Pomper, MD, PhD; Chris G. Ullman, PhD; IL Minn, PhD; | Immune-stimulants and immune modulators | Cytokine; Gene expression; Immune adjuvant; Solid tumors |
| P622 | Characterization and comparison of NKTR-255, a polymer-conjugated IL-15 versus IL-15 superagonist | Takahiro Miyazaki, MS; Mekhala Maiti, PhD; Sara Sheibani; Joanna Wilczek; Olga Zemska; Peiwen Kuo, PhD; Saul Kivimäe; Marlene Hennessy, BS; Phi Quach, BS PhD; Ping Zhang, MS PhD; Thomas Chang, PhD; Loui Madakamutil; Jonathan Zalevsky, PhD; | Immune-stimulants and immune modulators | Cytokine; NK/NK T cell; T cell |
| P623 | Bempegaldesleukin in combination with local radiation and systemic checkpoint blockade induces a robust systemic anti-tumor immunity. | Alexander Pieper, BS.; Alexander L. Rakhmilevich, MD, PhD; Dan Spiegelman; Ravi Patel, MD, PhD; Claire Baniel; Amy K. Erbe, PhD; Jacquelyn A. Hank, PhD; Deborah Charych, PhD; Willem W. Overwijk, PhD; Zachary S. Morris, MD, PhD; Paul M. Sondel, MD, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; Radiotherapy; Solid tumors; T cell; Vaccine |
| P624 | Layer-by-layer nanoparticles for the non-toxic delivery of interleukin-12 to orthotopic ovarian cancer | Sean G. Smith, PhD; Antonio E. Barberio, BSE; Sean G. Smith, PhD; Darrell J. Irvine, PhD; Santiago Correa; Cathy Nguyen; Mariane Melo; Talar Tokatlian, PhD; Paula T. Hammond; | Immune-stimulants and immune modulators | Cytokine; Immune adjuvant; Immune toxicity; Solid tumors |
| P625 | KY1043, a novel PD-L1 IL-2 immunocytokine directed towards CD25, delivers potent anti-tumour activity in vitro and in vivo | Cassandra H. Van Krinks, PhD; Timothy Malcolm; Morgane Lecointre; Richard Brown; Hanif Ali; Hannah Craig; Dirk Zahn; Siobhan O'Leary; Lucy Hepburn; Rachael Kimber; Nikole Sandy; Alla Fane-Dremucheva; Jamie Campbell, PhD, BS; Volker Germaschewski, PhD, MSc; Stephen D. Gillies, PhD; Matthew J. McCourt, BSc; Matthew J. McCourt, BSc; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; T cell; T cell lineages; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P626 | Substantial improvement of cancer immunotherapy by an RNA encoded extended half-life Interleukin-2 variant. | Mathias Vormehr, PhD; Lena M. Kranz; Alexander Muik, PhD; Sina Fellermeier-Kopf; Nadja Salomon; Jan Diekmann; Claudia Lindemann; Sonja Witzel; Marlen Lepper; Friederike Gieseke; Veronika Jahndel; Özlem Türeci; Ugur Sahin; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; Immune adjuvant; Neoantigens; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor antigens; Vaccine |
| P627 | Comparing the functionality of Proleukin® and Akron Interleukin-2 through an analysis of key T cell subsets | Claudia Zylberberg, PhD; John Koreth, MBBS, DPhil; Jerome Ritz, MD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Autoimmunity; Biomarkers; CAR T cells; Cytokine; Immune adjuvant; Immune toxicity; Regulatory T cell (Treg cell); T cell; Targeted therapy |
| P628 | Inhibition of histone deacetylase enhances CD8 T-cell functionality and metabolic fitness resulting in strong anti-tumor response. | Pankaj Gaur, PhD; Vivek Verma, PhD; Rahul Nnadre; Fatmah Alolaqi; Peter Ordentlich, PhD; Lei Wang, PhD; Seema Gupta, PhD; Samir N. Khleif, MD; | Immune-stimulants and immune modulators | Gene expression; Metabolism; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Vaccine |
| P629 | Therapeutic Vascular Normalization to Promote Tumor-Associated Tertiary Lymphoid Structures | Jessica Filderman, BS; Walter J. Storkus, PhD; Jessica Filderman, BS; | Immune-stimulants and immune modulators | Angiogenesis; Dendritic cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P630 | Induction of antitumor immune response by selective HDAC6 inhibition | Gianluca Fossati, Dr; Chiara Ripamonti; Gianluca Caprini; Andrea Stevenazzi; Barbara Vergani; Luigi Aurisicchio; Fabio Palombo, PhD; Antonella Conforti; Christian Steinkuhler; Gianluca Fossati, Dr; | Immune-stimulants and immune modulators | Neoantigens; Solid tumors; T cell; Targeted therapy |
| P631 | Immunotherapy plus gene therapy: A novel nanomedicine carrying the RB94 gene that suppresses tumor growth in non-small-cell lung cancer by inducing immunogenic cell death & modulating host immunity | Joe B. Harford, PhD; Caroline Doherty; Manish Moghe; Antonina Rait, PhD; Steven Metallo, PhD; Kathleen F. Pirollo, PhD; Esther H. Chang, PhD; Sang-Soo Kim, PhD; | Immune-stimulants and immune modulators | Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; NK/NK T cell; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment |
| P632 | Acute myeloid leukemia induced T cell suppression can be reversed by inhibition of the MAPK pathway | Kaycee Moshofsky, BS, MCR; Kyle A. Romine, BS; Yoko Kosaka, PhD; Guanming Wu; Shannon McWeeney, PhD; Evan F. Lind, PhD; | Immune-stimulants and immune modulators | Immune suppression; Leukemia/Lymphoma; T cell; Tumor evasion; Tumor microenvironment |
| P633 | BPM31510, a Metabolic Modulating Anti-Cancer Agent, Demonstrates Immune Potentiating Properties by Promoting Cytotoxic T Cells and Reversing Indices of Exhaustion and Immunosuppression | Maria-Dorothea Nastke, PhD; Maria-Dorothea Nastke, PhD; Shiva Kazerounian, PhD; Anne R. Diers, PhD; Stephane Gesta, PhD; Vivek Vishnudas, PhD; Niven R. Narain, PhD; Rangaprasad Sarangarajan, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; Immune adjuvant; Immune suppression; Immune tolerance; Metabolism; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P634 | Predicting radiation-induced immune trafficking and activation in localized prostate cancer | Simon P. Keam; Heloise Halse; ThuNgoc Nguyen; Catherine Mitchell; Franco Caramia; David J. Byrne; Sue Haupt; Georgina Ryland; Phillip K. Darcy; Shahneen Sandhu, MBBS FRACP; Piers Blombery; Ygal Haupt; Scott G. Williams; Paul J. Neeson, PhD; | Immune-stimulants and immune modulators | B cell; Immune contexture; Immune suppression; Monocyte/Macrophage; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P635 | The impact of beta blockers on survival outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors | Michael S. Oh, MD; Alex Guzner; Derek A. Wainwright, PhD; Nisha A. Mohindra, MD; Young Kwang Chae, MD; Amir Behdad; Victoria Villaflor, MD; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors |
| P636 | Inhibitors of Ataxia-Telangiectasia Related (ATR) protein lead to innate immune pathway activation and enhanced response to immune therapy in prostate cancer | Patrick G. Pilie, MD; Zhe Tang; Sanghee Park; Cheng Wu; Zhenyang Dong; Timothy A. Yap, MD PhD; Paul Corn; Timothy C. Thompson; | Immune-stimulants and immune modulators | Autoimmunity; Checkpoint blockade; Costimulation; Solid tumors; Targeted therapy |
| P637 | Immunomodulation of solid tumors by carbon-ion therapy versus conventional photon therapy | Catherine S. Spina, MD, PhD; Chizuru Tsuruoka; Wendy Mao; Masaaki Sunaoski; Mathew Chaimowitz; Yi Shang; Shizuko Kakinuma; Charles G. Drake, MD, PhD; Catherine S. Spina, MD, PhD; | Immune-stimulants and immune modulators | Radiotherapy; Tumor infiltrating lymphocytes (TILs) |
| P638 | Integrin-mediated augmentation of antigenic immunity | Upendra K. Marathi, Ph.D; Yared Hailemichael, PhD; Nandadeva Lokugamage; Michael Schotsaert; Angela Choi; Imran Chwdhury; Nisha Garg; Adolfo Garcia-Sastre; Lionel Lewis; Siddhartha De; Peter Vanderslice, PhD; Jeffrey Actor; Darren G. Woodside, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Antibody; Antigen presenting cells; B cell; Checkpoint blockade; Costimulation; Immune adjuvant; T cell; Vaccine |
| P639 | Depth of tumor implantation predicts response to in situ vaccination in a syngeneic melanoma model - an important variable influencing response to immunotherapy | Peter M. Carlson, BS; Manasi Mohan; Mat Rodriguez; Vladimir Subbotin; Amy K. Erbe, PhD; Zachary S. Morris, MD, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Dendritic cell; Radiotherapy; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Vaccine |
| P640 | Intratumoral application of the RNA-based TLR-7/-8 and RIG-I agonist CV8102 promotes a pro-inflammatory tumor microenvironment and causes a durable anti-tumor response | Michael Meister, PhD; Mohamed Habbeddine, PhD; Katja Fiedler; Johannes Lutz; Mallika Ramakrishnan; Regina Heidenreich; Michael Meister, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Chemokine; Cytokine; Gene expression; Immune adjuvant; TLR; Tumor microenvironment |
| P642 | Potent tumor-directed T cell activation and tumor inhibition induced by ALG.APV-527, a 4-1BB x 5T4 ADAPTIR™ bispecific antibody | Michelle H. Nelson, PhD; Robert Miller; Robert Bader; Doreen Werchau, BS; Anneli Nilsson; Lill Ljung; Adnan Deronic, PhD; Allison Chunyk; Lena Schultz; Catherine McMahan; David Bienvenue; Anna Dahlman; Sara Fritzell; Maria Askmyr; Gabriela Hernandez-Hoyos; | Immune-stimulants and immune modulators | Antibody; Costimulation; NK/NK T cell; T cell; Targeted therapy; Tumor antigens |
| P643 | Harnessing pre-existing anti-viral immunity for tumor therapy | Cuburu Nicolas, PhD; Lukas Bialkowski; Sergio Pontejo, PhD; Rina Kim, BS; Alexander Bell; Cynthia D. Thompson; Douglas R. Lowy, MD; John Schiller, PhD; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Tumor microenvironment; Vaccine |
| P644 | Collagen anchoring of intratumorally administered agonist antibodies improves efficacy and limits toxicities | Joseph R. Palmeri, BS; Karl D. Wittrup, PhD; | Immune-stimulants and immune modulators | Costimulation; Immune toxicity; Solid tumors; T cell; Tumor microenvironment |
| P645 | A tumor necrosis factor alpha mimetic as anti-tumor immune adjuvant | Ketki Velankar, MS; Ngoc B. Pham, BS; Ellen S. Gawalt; Wilson Meng, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Costimulation; Dendritic cell; Immune adjuvant; Immune suppression; Monocyte/Macrophage; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Vaccine |
| P646 | Reprogramming CD8 cells into metabolically fit stem cell memory with superior therapeutic activity by MEK1/2 manipulation. | Vivek Verma, PhD; Pankaj Gaur, PhD; Jose Lopez; Fatmah Alolaqi; Seema Gupta, PhD; Samir N. Khleif, MD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Stem cell/cancer-initiating cell; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| P647 | Is intracellular STING expression a biomarker for oncolytic herpes virus immunotherapy? | Praveen K. Bommareddy, MS, PhD; Samuel Rabkin, PhD; Andrew Zloza, MD, PhD; Howard L. Kaufman, MD, FACS; | Immune-stimulants and immune modulators | Biomarkers; T cell; Tumor microenvironment |
| P648 | Therapeutic efficacy of oncolytic vaccinia virus requires infection and removal of deleterious host immune cells | Kristin DePeaux, BS; Greg M. Delgoffe, PhD; Saumendra Sarkar, PhD; Steve Thorne, PhD; Paolo DA. Vignali, BA; Dayana Rivadeneira, PhD; Kristin DePeaux, BS; | Immune-stimulants and immune modulators | Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P649 | Targeting Subtypes of Circulating Myeloid Cells during Oncolytic Vaccinia Virus Therapy | Tae-Ho Hwang, PhD, DDS; Bora Lee; Fen Jiang; Mong Cho, MD, PhD; Euna Cho; Tae-Ho Hwang, PhD, DDS; | Immune-stimulants and immune modulators | Immune adjuvant; Myeloid cells; Solid tumors |
| P650 | Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas Induced by Oncolytic Adenovirus Delta-24-RGDOX | Hong Jiang, PhD; Dong Ho Shin; Teresa Nguyen, BS; Frederick Lang, MD; Candelaria Gomez-Manzano, MD; Juan Fueyo; | Immune-stimulants and immune modulators | Antigen presenting cells; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P651 | Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming | Eric Quemeneur, PharmD, PhD; Patricia Kleinpeter, MSc; Jean Baptiste Marchand, PhD; Laetitia Fend; | Immune-stimulants and immune modulators | Checkpoint blockade; Costimulation; Immune contexture; Immune suppression; Tumor microenvironment; Vaccine |
| P652 | The fully human antibody SRF617 is a potent enzymatic inhibitor of CD39 with strong immunomodulatory activity | Michael C. Warren; Sonia Das; Austin Dulak; Tauqeer H. Zaidi; Erik Devereaux; Jamie Strand; Benjamin Lee, MD PhD; Secil Koseoglu; Pamela Holland, PhD; Vito J. Palombella, PhD; Andrew C. Lake, PhD; | Immune-stimulants and immune modulators | Antibody; Dendritic cell; Immune suppression; Inflammation; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| P653 | Labeling method for flow cytometric analysis of radioactive tumors following immunotherapy and molecular targeted radionuclide therapy (mTRT): demonstration of augmented immune infiltrate | Peter M. Carlson, BS; Manasi Mohan; Ravi Patel, MD, PhD; Lauren Nettenstrom; Dagna Sheerar; Kathryn Fox; Mat Rodriguez; Anna Hoefges, MS; Reinier Hernandez, PhD; Chris Zahm, PhD; Douglas G. McNeel, MD, PhD; Jamey Weichert, PhD; Zachary S. Morris, MD, PhD; Paul M. Sondel, MD, PhD; | Immune-stimulants and immune modulators | Immune adjuvant; Immune monitoring; Radiotherapy; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Vaccine |
| P654 | CD137 agonists as an adjunct to immune checkpoint inhibitors to overcome resistance in melanoma | Sreedevi Danturti, PhD; Lena Sophie Mayer, MD; Sreedevi Danturti, PhD; Vesselin Tomov; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Checkpoint blockade; Chemokine; Costimulation; Cytokine; Monocyte/Macrophage; Myeloid cells; T cell; T cell lineages; Targeted therapy |
| P655 | EOS100850, an A2A receptor antagonist demonstrates efficacy in murine syngeneic tumor models regardless of adenosine concentrations | Romain Pirson, MSc; Anne Catherine Michaux; Diane Jamart; Julie Preillon, MSc.; Lucas Chaible; Chiara Martinoli, PhD; Gregory Driessens, PhD; Erica Houthuys, PhD; Stefano Crosignani, PhD; Reece Marillier, PhD; | Immune-stimulants and immune modulators | Chemotherapy; Immune suppression; Immune tolerance; Metabolism; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P656 | PEGylated cationic liposomal-oxaliplatin display impressive anti-cancer efficacy by dual-targeting of immunosuppressive populations and cancer-cells | Lars R. Petersen, PhD; Lars Ringgaard, PhD; Fredrik Melander, PhD; Ragnhild G. Østrem, PhD; Kasper Kristensen, PhD; Jonas R. Henriksen, PhD; Dennis R. Elema, PhD; Andreas Kjær, MD, PhD; Thomas L. Andresen, PhD; | Immune-stimulants and immune modulators | Chemotherapy; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor antigens; Tumor microenvironment |
| P657 | Selective T cells Redirection Proteins (STR) Enhance the Anti-Tumor Activity of Checkpoint Inhibitors (CPIs) and can Lead to Long-Lasting Immunity Against the Tumor | Meir Azulay, Ph.D; | Immune-stimulants and immune modulators | Antibody; Antigen presenting cells; Checkpoint blockade; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P658 | Co-delivery of synergistic immune agonists via systemic nanoparticles for interferon β-driven anti-tumor immunity and prevention of metastasis | Prabhani Atukorale; Chris J. Hoimes, MD; Prabhani Atukorale; Efstathios Karathanasis; | Immune-stimulants and immune modulators | Antigen presenting cells; Cytokine; Dendritic cell; Immune adjuvant; Monocyte/Macrophage; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment; Vaccine |
| P659 | ENPP1 antagonists in combination with radiation or checkpoint inhibitors demonstrate antitumor activity in syngeneic mice models of pancreatic adenocarcinoma, neuroblastoma, TNBC, and colon cancer | Lingyin Li, PhD; Mark Smith, PhD; Betty Chang, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Dendritic cell; Radiotherapy; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P660 | TNF-alpha suppresses the Immunogenicity of STING-agonists | Anthony L. Desbien, PhD; Kelsey E. Sivick Gauthier; Ed Lemmens; Weiqun Liu, PhD; Brian Francica, PhD; Gabrielle L. Reiner; Charles Cho; Steven L. Bender; Jeffry M. Mckenna, DPhil; Yan Feng, PhD; Lianzing Zheng, Phd; Andrea van Elsas; Sarah McWhirter; | Immune-stimulants and immune modulators | Immune adjuvant; T cell |
| P661 | Development and characterization of next generation small molecule STING agonists | Stefan Chmielewski, PhD; Magdalena Zawadzka; Jolanta Mazurek; Karolina Gluza; Katarzyna Wójcik-Jaszczynska; Maciej Kujawa; Grzegorz Topolnicki; Grzegorz Cwiertnia; Aleksandra Poczkaj; Eliza Zimolag; Magdalena Mroczkowska; Agnieszka Gibas; Marcin Les; Sylwia Sudol; Marek Wronowski; Kinga Michalik; Katarzyna Banaszak; Katarzyna Wiklik; Federico Malusa; Michal Combik; Karolina Wiatrowska; Lukasz Dudek; Jose Alvarez; Anna Rajda; Maciej Rogacki; Faustyna Gajdosz; Aniela Golas; Katarzyna Wnuk-Lipinska; Ewelina Gabor-Worwa; Charles Fabritius; Luigi Stasi; Peter Littlewood; Krzysztof Brzózka; Monika Dobrzanska; | Immune-stimulants and immune modulators | Antigen presenting cells; Cytokine; Dendritic cell; Inflammation; Monocyte/Macrophage; Tumor evasion; Tumor microenvironment |
| P662 | Inhibiting DNA methylation can reverse epigenetic silencing of STING in melanoma and enhance antitumor T-cell activity | Rana Falahat, PhD; James Mulé, PhD; Anders E. Berglund, PhD; Patricio Perez-Villarroel; Shota Aoyama, MD; Shari A. Pilon-Thomas, PhD; Glen N. Barber, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Bioinformatics; Chemokine; Cytokine; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion |
| P663 | Evaluating loss of cGAS and STING expression using a novel multiplex immunohistochemistry detection approach | Jeanette Rheinhardt; Adam Markman; Hideki Goda, PhD; Etsuko Futaya; Masaru Takahashi; Hiroyuki Yokota; Kenji Nishikawa; Hisatake Okada; Kenneth Bloom; George Abe; Joseph Krueger; Apollina Goel, PhD; | Immune-stimulants and immune modulators | Biomarkers; Immune adjuvant; Immune contexture; Tumor infiltrating lymphocytes (TILs) |
| P664 | Development of small molecule STING agonists that can evoke host anti-cancer immune defences following local or systemic delivery | Nicole M. Haynes, PhD; Theresa Connor; Ben Morrow, PhD; Judy Doherty; Matthew Dennis, PhD; Jonathan Hubert, PhD; Sukhdeep Spall; Anthony Cuzzupe; Karen White, PhD; Susan Charman, PhD, Professor; Aaron Lock; Vicky M. Avery, PhD, Professor; Stewart Nuttall; Tom S. Peat, PhD; Olan Dolezal, PhD; Pat Pilling; Jezrael Revalde; Tin Yow; Greg Arndt; Hendrik Falk, PhD; Mark Devlin, PhD, COO; Ian P. Street, PhD; Poh S. Khoo, PhD; Paul A. Stupple, PhD; Brendon J. Monahan, PhD, CSO; | Immune-stimulants and immune modulators | Antigen presenting cells; Cytokine; Dendritic cell; Immune adjuvant; Inflammation; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P665 | Enhancing IFN-β production through synergy between the STING and TLR pathways | Emily Higgs, BA; Thomas F. Gajewski, MD, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Dendritic cell; Immune adjuvant; TLR |
| P666 | Selective activation of antigen presenting cells by exoSTING enhances tumor antigen-specific immune response | Su Chul Jang, PhD; Kelvin Zhang; Nuruddeen Lewis, PhD; Tong Zi; Joanne Lim; Rane Harrison; Raymond J. Moniz; Katherine Kirwin; Chang Ling Sia; Christine McCoy; Kevin Dooley; Ke Xu; Jorge Sanchez-Salazar; Raymond W. Bourdeau; Agata Villiger-Oberbek; William K. Dahlberg; Shil Patel; Kyriakos Economides; Sriram Sathyanarayanan; | Immune-stimulants and immune modulators | Antigen presenting cells; Checkpoint blockade; Dendritic cell; Gene expression; Monocyte/Macrophage; Myeloid cells; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P667 | Neoadjuvant STING agonists combined with systemic immunotherapy block metastatic recurrence in orthotopic breast tumors | Lauren Milling, BS; Darrell J. Irvine, PhD; | Immune-stimulants and immune modulators | Cytokine; Dendritic cell; Surgery; T cell; Tumor microenvironment |
| P668 | TTI-10001, a next generation small molecule STING agonist, demonstrates potent anti-tumor activity in mice following oral or intravenous administration | Natasja Viller; Peter Dove; David Rosa; Bolette Bossen, BSc; Tran Truong; Tapfuma Mutukura; Debbie Jin; Marilyse Charbonneau; Laura Brinen; Karen Dodge; Gloria HY. Lin; Jeff Winston; Robert A. Uger; Malik Slassi; Zezhou Wang, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Antigen presenting cells; Cytokine; Dendritic cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P669 | Pharmacological evaluation of the ubiquitin ligase CBL-B as a small molecule, tumor immunotherapy target | Jennifa Gosling, MS; Christoph W. Zapf; Ryan Rountree; Chenbo Wang; Thomas Cummins; Frederick Cohen; Hiroko Tanaka; Dahlia Weiss; Mario Cardozo; Christopher Karim; May Tan; Austin Tenn-McClellan; Szerenke Kiss von Soly; Julie Sheung; Ketki Dhamnaskar; Katherine Kurylo; Neil Bence; Arthur Sands; | Immune-stimulants and immune modulators | Cytokine; NK/NK T cell; T cell |
| P670 | Pharmacodynamic response in vitro and in vivo of novel orally administered Toll-like Receptor 7 agonists for systemic immunotherapy of cancer | James R. Appleman, PhD; Stephen E. Webber; | Immune-stimulants and immune modulators | Chemokine; Cytokine; Dendritic cell; TLR |
| P671 | Delivery of TLR7 agonists by Deep-Primed™ T cells induces immune activation and improves anti-tumor activity in mice while circumventing systemic toxicity | Austin W. Boesch, PhD; Vasily Rybakin; Nathan Westcott; Ji Young Hwang; Kira Jørgensen; Rasmus Lassen; Martin Kraemer; Martin Bak, PhD; Gael Veiga; Jonas Bruun, PhD; Carlos Tassa; Harrison Rodts; Manny Sequeira; Glenn Leary; Santina Caruso; Becker Hewes, MD; Jonathan B. Fitzgerald, PhD; Karsten Sauer, PhD; Thomas L. Andresen, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Antigen presenting cells; Cytokine; Dendritic cell; Immune toxicity; MDSC; T cell; TLR; Tumor antigens; Tumor microenvironment |
| P672 | Activation of CD8+ T cells in the presence of multiple TLR agonists differently affects the expression of T-cell checkpoint receptors | Donghwan Jeon, MS; Christopher W. Zahm, PhD; Douglas G. McNeel, MD, PhD; Donghwan Jeon, MS; | Immune-stimulants and immune modulators | Dendritic cell; Immune adjuvant; TLR |
| P673 | Targeted delivery system for toll-like receptor agonists to repolarize the immunosuppressive phenotype of tumor-associated macrophages | Hyewon Ko; Soyoung Son; Sol Shin; Jae Hyung Park, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Checkpoint blockade; Immune adjuvant; Immune suppression; Monocyte/Macrophage; Targeted therapy; TLR; Tumor microenvironment |
| P674 | In situ vaccination using a tumor-binding polymeric glyco-adjuvant for the induction of anti-tumor immunity | Tiffany Marchell; David S. Wilson; Aaron Alpar; Jeffrey Hubbell; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment; Vaccine |
| P675 | Multimodal intratumoral immunotherapy potentiates complete immunologic tumor elimination of breast cancer origin diffuse liver metastases | Erik R. Soule; Jason R. Williams, MD; | Immune-stimulants and immune modulators | Antibody; Biomarkers; Checkpoint blockade; Immune adjuvant; Neoantigens; Regulatory T cell (Treg cell); Stem cell/cancer-initiating cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Vaccine |
| P676 | Intratumoral delivery of TransCon™ TLR7/8 Agonist provides potent anti-tumor activity as a monotherapy and in combination with IL-2 while minimizing systemic cytokine induction | Luis A. Zuniga, PhD; Torben Leßmann; Lars Holten-Andersen; Nicola Bisek; Joachim Zettler; Sebastian Stark; Frank Faltinger; Oliver Kracker; Samuel Weisbrod; Robin Müller; Tobias Voigt; Kornelia Bigott; Mohammad A. Tabrizifard; Vibeke Breinholt; Kennett Sprogøe; Juha Punnonen; | Immune-stimulants and immune modulators | Antigen presenting cells; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P677 | Warehouse approach for the development of personalized cancer vaccines by using Personal Antigen Selection Calculator (PASCal) without need for tumor biopsy | Zsolt Csiszovszki, PhD; Levente Molnár; Péter Páles; József Tóth; Orsolya Lorincz; Katalin Pántya; Eszter Somogyi; István Miklós; Wolfgang Schönharting; Sybille Urban; Tim Röhnisch; Mónika Megyesi; Eniko R. Toke; | Immune-stimulants and immune modulators | Bioinformatics; Immune adjuvant; Solid tumors; T cell; Tumor antigens; Vaccine |
| P678 | Vaccine neoantigens empirically identified through the ex vivo ATLAS platform promote potent therapeutic responses to cancer in mice | Victoria L. DeVault, PhD; Hanna Starobinets, PhD; Sanmit Adhikari; Brendan Classon, PhD; Jessica B. Flechtner, PhD; Hubert Lam, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Immune suppression; Immune tolerance; Neoantigens; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| P679 | Scheduling androgen deprivation with AR-targeted vaccination affects anti-tumor efficacy in prostate cancer | Melissa Gamat-Huber, PhD; Douglas G. McNeel, MD, PhD; Melissa Gamat-Huber, PhD; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors; T cell; Vaccine |
| P680 | Discovery of immunogenic ERV-derived antigens as targets for melanoma immunotherapy | Ray Jupp, PhD; George Kassiotis; Nicola Ternette; George Young; Duncan Howie; Fabio Marino; Matthew Davies; Hayden Selvadurai; Alvaro Sanchez; Jonathan Dodd; Laura Lozza; Elizabeth Soilleux; Peter W. Mason; Kevin Pojasek; | Immune-stimulants and immune modulators | T cell; Tumor antigens; Vaccine |
| P681 | DNA Methyltransferase Inhibition Immunosensitizes Diffuse Intrinsic Pontine Gliomas to Peptide Vaccine through Augmentation of EphA2 and MHC I Expression. | Rajeev Kumar; Lauren McCarl; Alexandra Foster; Shubhanchi Nigam; Xinjuan Ma; Marissa Campagna; Alberto Broniscer; Katherine Warren; Ian Pollack; Gary Kohanbash; | Immune-stimulants and immune modulators | Pediatric tumors; Tumor antigens; Vaccine |
| P682 | AI-augmented design of effective therapeutic cancer vaccines and adoptive cell therapies | Piotr Stepniak; Giovanni Mazzocco, M.Sc.; Alexander Myronov, M.Sc.; Iga Niemiec, M.Sc.; Katarzyna Gruba, M.Sc.; Piotr Skoczylas, M.Sc.; Anna Sanecka-Duin, PhD; Michal Drwal, M.Sc.; Jan Kaczmarczyk, PhD; Giovanni Mazzocco, M.Sc.; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Bioinformatics; Immune adjuvant; Neoantigens; T cell; Vaccine |
| P683 | Incomplete Freund’s Adjuvant reduces Arginase, enhances a Th1 dominant cytokine environment, and supports CD40 L expression | Karlyn E. Pollack, MD; Max O. Meneveau, MD; Alexander F. Koeppel; Samuel J. Young; Stephen D. Turner; Katia Sol-Church, MD; Ileana S. Mauldin, PhD; Craig L. Slingluff, Jr., MD; | Immune-stimulants and immune modulators | Chemokine; Dendritic cell; Gene expression; Immune adjuvant; Solid tumors; T cell; TLR; Vaccine |
| P684 | Highly efficient selection of tumor neoantigens improves therapeutic cancer vaccine efficacy | Guilhem Richard, PhD; Gad Berdugo, MSc, MBA; Michael F. Princiotta, MS, PhD; Leonard Moise, PhD; Matthew Ardito, BA; Christine Boyle; Dominique Bridon; William Martin, BA MD; Anne S. de Groot, MD; | Immune-stimulants and immune modulators | Bioinformatics; Neoantigens; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy |
| P685 | Inhibition of EZH2 enhances tumor immunogenicity through diversification of tumor antigen presentation | Jing Qiu, PhD; Thomas Paul; | Immune-stimulants and immune modulators | Immune suppression; Neoantigens; Vaccine |
| P686 | The NCI PREVENT Program portfolio for precision cancer immunoprevention | Shizuko Sei, MD; Altaf Mohammed, PhD; Jennifer Fox, PhD; Romaine I. Fernando, PhD; Daniel Boring, RPh, PhD; Mark Miller, PhD; Robert Shoemaker, PhD; | Immune-stimulants and immune modulators | Neoantigens; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Tumor microenvironment; Vaccine |
| P687 | Novel vaccination strategies using tumour-independent antigens to induce anti-tumour immunity in solid tumours. | Vinod Sommandas; Satwinder K. Singh; Erik Manting; Satwinder K. Singh; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors; Vaccine |
| P688 | Lysosomal-associated membrane protein-1-targeting of a poly-neoepitope DNA vaccine elicits potent immune responses and inhibits tumor growth | Pratima Sinha, PhD; Matthew Ardito, BA; Guilhem Richard; Leonard Moise, PhD; Gad Berdugo, MSc, MBA; Teri Heiland; | Immune-stimulants and immune modulators | Bioinformatics; Neoantigens; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Vaccine |
| P689 | Amphiphile-modifications target mKRAS-antigen and adjuvant to lymph nodes and enable polyfunctional mKRAS-specific immune responses with potent cytolytic activity | Martin Steinbuck; Peter DeMuth, PhD; Lochana Seenappa, MS; Martin Steinbuck; | Immune-stimulants and immune modulators | Immune adjuvant; T cell; Tumor antigens; Vaccine |
| P690 | Improving the immunogenicity of modified vaccinia virus Ankara (MVA) vaccine vector by deletion of the vaccinia E5R gene encoding a dominant cGAS inhibitor | Liang Deng, PhD, MD; Ning Yang; Yi Wang, MS; Peihong Dai; Stewart Shuman, MD PhD; | Immune-stimulants and immune modulators | Dendritic cell; Immune adjuvant; Tumor antigens |
| P691 | Monoclonal microbial EDP1503 induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity | Humphrey A. Gardner, MD; Shubhra Kashyap, MS; Peter Sandy, PhD; Holly Ponichtera, PhD; Shannon Argueta, PhD; Chris Davitt, PhD; Michael Goldberg, PhD; Mark Carlson, MS; Maria Sizova, PhD; Valeria Kravitz, MS; Erin Troy, PhD; Sam Andrewes, MS; Mark Bodmer, PhD; Loise Francisco-Anderson, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Immune adjuvant; NK/NK T cell; Tumor infiltrating lymphocytes (TILs) |
| P692 | Blockade of PGE2 Production and Signaling Enhances the Magnitude and Selectivity of BCG-Promoted Immune Responses in the Human Bladder Cancer Microenvironment | Omar M. Ibrahim, BPharm; Melissa Grimm, PhD; Weijan Jiang; Khurshid Guru; Gurkamal S. Chatta, MD; Pawel Kalinski, MD, PhD; | Immune-stimulants and immune modulators | Inflammation; TLR; Tumor microenvironment |
| P857 | ONM-500 - A Novel STING-activating therapeutic nanovaccine platform for cancer immunotherapy | Jason Miller, PhD, Min Luo, Hua Wang, Zhaohui Wang, Xinliang Ding, PhD, Ashley Campbell, Jonathan Almazan, Zhijian Chen, Jinming Gao, Tian Zhao | Immune-stimulants and immune modulators | Antigen presenting cells; Immune adjuvant; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
© 2019 Society for Immunotherapy of Cancer (SITC). All rights reserved. SITC Meeting Code of Conduct.
